IDNAvsIGIB
iShares Genomics Immunology and Healthcare ETF against iShares 5-10 Year Investment Grade Corporate Bond ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| IDNA | IGIB | |
|---|---|---|
| Expense ratio | 0.47% | 0.040% |
| Assets | $317M | $18.6B |
| Net flow, 1 month | +$49M | +$534M |
| Net flow, 1 year | +$106M | +$3.4B |
| Return, YTD | +56.1% | -6.6% |
| Return, 1 year | +66.5% | -6.7% |
| Avg daily volume | 195K | 4.1M |
| Holdings | 63 | 2744 |
| Listed | Jun 11, 2019 | Jan 5, 2007 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS